GlassScriptPhysician profile
Latoya Polanco
NPI 1578954830
$1,088.63
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.13 · 2022: $299 · 2023: $531 · 2024: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $469.38 | 2021-2024 | Myrisk |
| Sirtex Medical INC | $119.15 | 2022 | |
| Integra Lifesciences Corporation | $102.35 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Tempus Ai, INC | $69.13 | 2024 | Xt Cdx |
| Merck Sharp & Dohme LLC | $54.25 | 2022-2024 | Keytruda |
| Boston Scientific Corporation | $48.39 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Kci USA, INC. | $47.51 | 2022-2023 | Abthera, V.A.C. Veraflo Cleanse Choice, Prevena |
| Solventum Corporation | $37.85 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice, V.A.C.Ulta |
| Medtronic, INC. | $30.31 | 2023 | Osteocool Rf Ablation System |
| Smith+Nephew, INC. | $20.32 | 2022 | |
| Angiodynamics, INC. | $19.19 | 2022 | |
| Emd Serono, INC. | $18.75 | 2023 | Bavencio |
| Eagle Pharmaceuticals, INC. | $18.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.32 | 2022 | |
| Vivus LLC | $16.50 | 2024 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Polanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.